ボセンタン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H302：飲み込むと有害

  H360：生殖能または胎児への悪影響のおそれ

  H410：長期的影響により水生生物に非常に強い毒性

• 注意書き

  P273：環境への放出を避けること。

  P281：指定された個人用保護具を使用すること。

ボセンタン 価格

ボセンタン 化学特性,用途語,生産方法

• 効能

  血圧降下薬, エンドセリン受容体拮抗薬

• 化学的特性

  Pale Yellow to Off-White Solid

• 使用

  A mixed endothelin receptor antagonist. Used as a vasodilator. Antihypertensive.

• 一般的な説明

  Bosentan, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tertbutyl-benzenesulfonamide (Tracleer, Bozentan), was thefirst endothelin receptor antagonist marketed in the UnitedStates. Bosentan works by competitively blocking the endothelinreceptor subtypes ETA and ETB. In binding to thereceptors, it blocks the effects of endothelin, which includeconstriction of the vascular smooth muscle, which leads tonarrowing of the blood vessels and hypertension. Althoughit is not selective for the ETA receptors, it does have a higheraffinity for that subtype over ETB. However, the clinical significanceof selectivity over preferential receptor bindinghas not been demonstrated. Bosentan is an inducer ofCYP2C9 and CYP3A4, and patients using bosentan must bemonitored for liver toxicity.

• 危険性

  A reproductive hazard.

• 薬物動態学

  Bosentan is mainly eliminated from the body by hepatic metabolism and subsequent biliary excretion of the metabolites. Three metabolites have been identified, formed by CYP2C9 and CYP3A4. The pharmacokinetics of bosentan are dose-proportional up to 500 mg/day (multiple doses). The pharmacokinetics of bosentan in pediatric patients with PAH are comparable to those in healthy subjects, whereas adult patients with PAH show a twofold increase in clearance. Severe renal impairment and mild hepatic impairment do not have a clinically relevant influence on its pharmacokinetics. Bosentan generally should be avoided in patients with moderate or severe hepatic impairment and/or elevated liver aminotransferases. Inhibitors of CYP3A4 increase the plasma concentration of bosentan as well as cause an increase in the clearance of drugs metabolized by CYP3A4 and CYP2C9 because of induction of these metabolizing enzymes. The possibility of reduced efficacy of CYP2C9 and CYP3A4 substrates coadministered with bosentan is increased. No clinically relevant interaction was detected for P-glycoprotein. Bosentan can increase plasma levels of ET-1.

• 臨床応用

  Bosentan is an orally administered, nonselective ET-1 receptor antagonist blocking ETA and ETB receptors and is approved for the treatment of patients with PAH. Following oral administration, bosentan attains peak plasma concentrations in approximately 3 hours, with an absolute bioavailability of approximately 50%. Food has no clinically relevant effect on its absorption recommended doses. Bosentan is approximately 98% bound to albumin, with a volume of distribution of 30 L. Its terminal half-life after oral administration is 5.4 hours and is unchanged at steady state.

• 副作用

  Adverse effects include hypotension, headache, flushing, increased liver aminotransferases, leg edema, and anemia. Bosentan may cause birth defects and, therefore, is contraindicated in pregnancy. It also can cause liver injury.

ボセンタン 上流と下流の製品情報

ボセンタン 生産企業

Global(255)Suppliers

ボセンタン スペクトルデータ(¹HNMR)

147536-97-8, ボセンタン キーワード